Credit: Shutterstock The U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to a promising new treatment for dry age-related macular degeneration (AMD)—a leading cause of vision loss. The therapy is being developed by Luxa Biotechnology and supported in part by the California Institute for Regenerative Medicine (CIRM). What RMAT Designation Means RMAT designation … Continue reading Luxa Biotechnology’s CIRM-funded Dry AMD Therapy Milestone
age related macular degeneration
CIRM invests $50 million in clinical research, including trial for vision loss
The California Institute for Regenerative Medicine (CIRM), the world’s largest institution dedicated to regenerative medicine, today awarded $50.1 million to fund clinical-stage research projects aimed at advancing stem cell and gene therapy treatments for a variety conditions ranging from neurodegenerative diseases and blood cancers to HIV/AIDS. The awards will support six projects in the Agency’s … Continue reading CIRM invests $50 million in clinical research, including trial for vision loss
CIRM funded trial for AMD shows promising results
This upcoming July is healthy vision month, a time to remember the importance of making vision and eye health a priority. It's also a time to think about the approximately 12 million people, 40 and over in the United States, that have a vision impairment. Vision can be something that many of us take for … Continue reading CIRM funded trial for AMD shows promising results